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The aorta stiffens with aging, a process that is accelerated by arterial hypertension. Decreased arterial compli-
ance is one of the earliest detectable manifestations of adverse structural and functional changes within the
vessel wall. The use of different imaging techniques optimized for assessment of vascular elasticity and quantifi-
cation of luminal and vessel wall parameters allows for a comprehensive and detailed view of the vascular sys-
tem. In addition, several studies have also documented the prognostic importance of arterial stiffness (AS) in
various populations as an independent predictor of cardiovascular morbidity and all-cause mortality. Measure-
ment of AS by applanation tonometry with pulse-wave velocity has been the gold-standard method and is well-
validated in large populations as a strong predictor of adverse cardiovascular outcomes. Because aortic stiffness
depends on the prevailing blood pressure, effective antihypertensive treatment is expected to reduce it in propor-
tion to the blood pressure reduction. Nevertheless, drugs lowering blood pressure might differ in their effects on
structure and function of the arterial walls. This review paper not only will discuss the current understanding and
clinical significance of AS but also will review the effects of various pharmacological and nonpharmacological
interventions that can be used to preserve the favorable profile of a more compliant and less stiff aorta.
(J Am Coll Cardiol 2011;57:1511–22) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2010.12.0173Understanding the Concept of Aortic Stiffness
Arterial stiffness is one of the earliest detectable manifesta-
tions of adverse structural and functional changes within the
vessel wall. Degenerative stiffness of the arterial beds is
referred as arteriosclerosis and it should be differentiated
from atherosclerosis, which is defined as the occlusive result
of endovascular inflammatory disease, lipid oxidation, and
plaque formation. Both tend to coexist and refer to a
progressive, diffuse, and age-related process that occurs in
all vascular beds (1).
Vessel walls are 3-dimensional structures with complex
vascular mechanics (2,3). For a better understanding of the
concept of aortic stiffness (AS), it is important to highlight
some key points:
1. Large arteries also have, aside from their properties of
providing a conduit for blood to reach peripheral tissues,
a critical role in providing adequate vascular buffering to
each ventricular contraction through arterial-ventricular
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accepted December 8, 2010.coupling. As such, the histological structure of the aorta
varies immensely according to its site and function as a
reservoir and conductive system (Windkessel principle).
For instance, the proximal aorta is rich in elastin that
allows the support of each systolic impulse and accom-
modates the stroke volume. Thus, the thoracic aorta and
its immediate branches show greater elasticity, whereas
more distal vessels become progressively stiffer, given the
predominance of collagen fibers (5,000 times the tensile
modulus of elastin) (2).
2. Stress () is defined as the force applied/area to a
particular object (  F/A). It can be applied in any
direction: at radial, circumferential, and longitudinal
components. Circumferential wall stress, defined by
Laplace’s law, is directly proportional to the vessel
pressure and radius and inversely proportional to its
thickness. Strain () is the resulting deformation (per-
centage change in length) of an object/material subjected
to a stress force. It is dimensionless (no units) and is
defined as:
LL0 ⁄ L0
where L is the final length and L0 is the initial length.
. The elastic modulus (E), also known as Young’s modu-
lus, is the stress/strain ratio. In most biologic materials,
this relation is nonlinear, and the slope defines the
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the wall material. E is ex-
pressed by the formula:
E

C
where C is the arterial com-
pliance.
4. Stiffness should be under-
stood as the resistance to de-
formation. Measures of arte-
rial stiffness depend on 3
independent and interdepen-
dent variables of the particular
vessel studied (E, h, and r).
The Moens-Korteweg equa-
tion defines pulse-wave veloc-
ity (PWV), assuming that
there are no significant changes in the vessel area or wall
thickness, as the following:
PWVEinc·h2r
where Einc is the incremental elastic modulus of the
vessel, h  vessel wall thickness, r  vessel radius, and
  density of blood. Units used are centimeters/second
or meters/second. Note that PWV is proportional to the
square root of vessel stiffness and not particularly sensi-
tive to changes in vessel dimensions or thickness. Aortic
stiffness is dependent on the complex interaction be-
tween the vascular smooth muscle cells with the extra-
cellular matrix containing elastin, collagen, and fibrillin
(FBN) fibers (3,4).
5. Arterial compliance (C) is the absolute change in area
(or change in diameter  D) for a given pressure step
(P) at a fixed vessel length. It is the reciprocal of
stiffness and is defined as:
C
D
P
Distensibility, by contrast, is defined as the relative
compliance or relative change in diameter/area/pressure
step increase. It is the inverse of the elastic modulus (E).
. The morphology of a pulse contour is that any point
along the vascular tree represents the sum of the forward
and reflected pressure waves at that point and depends on
3 factors: the amplitude and duration of left ventricular
(LV) ejection, the amplitude of the reflected wave, and
the velocity of the reflected wave from the periphery. The
end-product—also known as augmentation index and
often used as a surrogate of aortic stiffness—can be
Abbreviations
and Acronyms
AD  aortic distensibility
AS  aortic stiffness
CFPWV  carotid-femoral
pulse-wave velocity
CPAP  continuous
positive airway pressure
CV  cardiovascular
FBN  fibrillin
LV  left ventricular
MRI  magnetic resonance
imaging
PWV  pulse wave velocity
SBP  systolic blood
pressureaffected by several other factors, such as heart rate, LV mejection fraction, and duration (5), losing its clinical
utility particularly in diabetic persons (6) and individuals
60 years of age (7).
. In the long term, pulsatility causes stretching of the
load-bearing elastic lamellae and mechanical stress on
the wall contributing to structural changes and stiffening
(8) (Figs. 1 and 2). Over time, all these factors contribute
to increased large-artery stiffness which worsens with
aging (Fig. 3) (9).
. Genetics seems to also play a role in the development
of AS. Polymorphisms of the matrix metalloprotein-9
gene were independent predictors of increased aortic
stiffness (10).
ow to Measure AS
WV is the most validated method to noninvasively quan-
ify arterial stiffness. It is considered the gold standard index
f AS, given its simplicity, accuracy, reproducibility, and
trong prediction of adverse outcomes (11–13). PWV can
e determined by measuring the pulse transit time from the
ressure waveforms at the 2 sites along a vascular segment.
he distance (L) is divided by the wave foot-to-foot time
T) it takes for that forward wave to reach the end
easuring point (PWV) (Fig. 4). Pulse wave velocity is
nversely related to vascular compliance. Hence, a stiffer
essel will conduct the pulse wave faster than a more
istensible and compliant vessel.
PWV is a regional functional measurement of arterial
tiffness over a certain arterial length, whereas strain, com-
liance, and distensibility are local markers of arterial
lasticity. Local AS has been characterized—to allow com-
arisons between indexes—as the inverse relation of aortic
istensibility (AD) (13,14) as demonstrated by the Bram-
ell–Hill equation (15) and expressed in meters/second:
PWV 
1
Distensibility
or D (3.57 ⁄ PWV)2
Redheuil et al. (16) showed that local aortic elastic properties
measured by magnetic resonance imaging (MRI) were mark-
edly decreased before the fifth decade of life, whereas concom-
itant increase in aortic arch PWV (increased AS) was seen
demonstrating that inverse relationship.
Other investigators (3,4) have proposed that aortic com-
pliance and distensibility are the absolute and relative
changes for pressure steps, respectively. Aortic distensibility
is the relative cross-sectional diameter (or area) change for a
given pressure step at fixed vessel length. The frequently
used formula that expresses this relationship is:
Aortic Distensibility
AomaxAomin
Aomin	 central pulse pressure
where Aomax  maximal aortic lumen and Aomin 
inimal aortic lumen.
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April 5, 2011:1511–22 Aortic Stiffness: Current PerspectivesAs with any quantification technique, care must be taken
to consider the methodology being used when comparing
results between patient groups and among different studies
(Table 1).
Figure 1 Physiologic Properties of the Aorta as a Reservoir and
The aorta is regionally heterogeneous and not a simple conduit for blood distribut
absorb the energy of left ventricular ejection and dampen pulsatile flow.
Figure 2 Insults Leading to Structural Changes in the Aorta an
Several processes can alter the homeostasis of aortic elastic properties leading tMeasurement of AS by applanation tonometry and
oscillometric method. The applanation tonometry princi-
ple for arteries followed directly from the ocular application,
given the propensity for a circular arterial segment to be
ductive System: The Windkessel Principle
e viscoelastic properties of the proximal aorta
Functioning
ased stiffness and decreased compliance. LV  left ventricular.Con
ion. Thd its
o incre
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of this technique can be found elsewhere (17).
With 2 different sites (carotid and femoral artery, for
example), the oscillometric method measures noninvasively
the pulse transit time from the pressure waveforms at the 2
sites and infers the velocity in the “conduit” (Fig. 5). Asmar
Figure 3 Estimation of an Age-Specific Reference Interval for P
Reprinted with permission from Khoshdel et al. (9). PWV  pulse wave velocity.
Figure 4 Noninvasive Determination of PWV Between
the Carotid Artery and the Terminal Aorta
Femoral artery is the terminal aorta. The measured distance is L. If T repre-
sents the time delay between the feet of the 2 waves, pulse wave velocity
(PWV)  L/T. Distensibility might be then deduced from the Bramwell-Hill for-
mula. Automatic PWV measurements are currently widely used. Reprinted with
permission from Safar M. Atherosclerosis, large arteries and cardiovascular
risk. In: Safar ME, Frohlich E, editors. Advances in Cardiology. Basel; Karger
AG, 2007:1–18.et al. (13) calculated PWV with the oscillometric method in
more than 400 individuals with excellent intra- and inter-
observer reproducibility and good correlation between the
automatic and manual approaches.
Normal values in the typical adult of middle-age are 4
m/s in the ascending aorta, 5 m/s in the abdominal aorta
and carotids, 7 m/s in the brachial artery, and 8 m/s in the
iliac arteries (18).
Ideally, the transit time should be coupled to a precise and
reproducible measurement of true vascular lumen length. An
important limitation to this method is that, because no vascular
imaging is performed, the vascular length traveled by the pulse
wave (i.e., the carotid to femoral distance) has to be approxi-
mated from a body surface measurement. Rigid measurements
with calipers are monodimensional and do not take into
account the 3-dimensional morphology of the aorta, carotid
and femoral arteries (particularly in the anteroposterior direc-
tion) or the potential tortuosity associated with older arteries.
This is also true for flexible tape measures, and it is a major
argument in favor of making such distance measurements on a
comprehensive aortic imaging dataset, such as those available
with MRI. Direct intravascular distance measurements will
always be much better than indirect external approximations.
Carotid-femoral pulse wave velocity (CFPWV) is con-
sidered to be a global estimate of arterial PWV through the
entire aorta. However, we should note that this PWV is
measured between 2 peripheral sites, with flow in the
carotid and femoral arteries being in opposite directions,
whereas the ascending aorta—a prime location of aortic
stiffening—is not directly accounted for in this approach.
Another important caveat to this method is the amplifi-WVcation phenomenon. This phenomenon occurs because the
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wave reflections in smaller, less elastic, and more muscular
distal arteries. Thus, it is inaccurate to use brachial pulse
pressure as a surrogate for aortic or carotid pulse pressure,
particularly in young subjects (4).
Measurement of AS and distensibility by echocardiography.
Pulse wave velocity can also be assessed noninvasively by
echocardiography with pulse wave Doppler. Although this
method has not been as commonly used, it seems to have good
correlation (r  0.83) with the applanation tonometry (19).
Furthermore, pulse wave Doppler allows quantification of
Noninvasive Methods to Assess Aortic StiffnessTable 1 Noninvasive Methods to Assess Aortic Stiffness
Diagnostic Tool Advantages
Applanation tonometry ● No radiation exposure to the patient.
● Relatively inexpensive, easy to use and reproducible
● Excellent portability and temporal resolution.
● Large amount of evidence supporting clinical signific
Echocardiography ● Same as for applanation tonometry.
● Identification of other associated changes such as le
impaired diastolic function, and so on.
● Tissue Doppler and strain imaging can provide furth
pre-clinical changes of aortic elastic properties (21,2
CMR ● No ionizing radiation to the patient.
● Full 3-dimensional visualization of the vessel permit
placed perpendicular to the vessel in a reproducible
● Assessment of both local distensibilities and regiona
different locations of the arterial tree (regional stiffn
● Other aspects—such as aortic wall strain, deformati
be evaluated.
CMR  cardiac magnetic resonance; PWV  pulse wave velocity.
Figure 5 Measurement of Aortic Stiffness by Carotid-Femoral O
(A) Neckpad placement; (B) thigh cuff placement; (C) aortic path length measure
Reproduced with permission from Skidmore Medical, Ltd., Bristol, United Kingdomregional PWV, which could be advantageous as a future
research tool (20). The main advantage of ultrasound tech-
niques is their wide availability, and the main limitation is the
incomplete visualization of the aortic arch.
Aortic stiffness has also been evaluated with advanced
echocardiography techniques such as tissue Doppler and
strain imaging in different populations (21,22). These tech-
niques are important research tools, with future clinical
applications remaining to be found.
Furthermore, assessment of AD by transthoracic and
transesophageal echocardiography has a high degree of
Disadvantages
nd prognostication.
● Accuracy becomes problematic because no true
measurement of vascular lumen length is obtained
between the 2 recording sites (overestimation of PWV
can be particularly inaccurate in obese patients).
tricular hypertrophy,
rmation on
● Not as extensively studied and validated as
applanation tonometry.
● Echocardiography windows could be challenging in
patients with advanced emphysema, morbid obesity,
breast implants, and so on.
● Particularly in young subjects, pulse pressure
amplification phenomenon occurs between central
and peripheral arteries. Thus, inaccuracy can result in
whichever method with brachial pulse pressure as a
surrogate for aortic or carotid pulse pressure
(i.e., echocardiography, CMR, and so on).
aging plane to be
n.
wave velocities at
d so on—can also
● Longer examination duration.
● Not feasible yet for patients with certain cardiac
devices (pacemakers, defibrillators, and so on).
metric Signal
(D) pulse wave velocity (PWV) analysis is displayed on the computer screen..
ance a
ft ven
er info
2).
s the im
locatio
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ess).
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.
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different populations (23). On transthoracic echocardiogra-
phy, M mode measurements are obtained at 3 cm above the
aortic valve on parasternal long-axis view (Fig. 6) (24). On
transesophageal echocardiography, measurements are done
at the level of pulmonary artery bifurcation (2 to 3 cm above
the aortic valve) and in the descending thoracic aorta just
distal to the branching site of the left subclavian artery (25).
The following formula, described by Stefanadis et al. (23), is
then applied:
Aortic Distensibility (in cm2dyne1106)

2	 (systolic diameter diastolic diameter)
(diastolic diameter)	 (brachial pulse pressure)
As mentioned previously, pulse pressure amplification
might confound these estimations when using brachial pulse
pressure, especially in young individuals.
Measurement of AS by MRI. Unlike CFPWV, which is
an average measure of overall arterial stiffness, MRI enables
the detection of more subtle changes in regional stiffness.
Magnetic resonance imaging has several advantages over
ultrasound in that full 3-dimensional visualization of the
vessel is possible, enabling the imaging plane to be placed
perpendicular to the vessel in a reproducible location. This
is an obvious advantage for the measurement of distensibil-
ity measured in MRI as a change in 2-dimensional vessel
perimeter or area instead of 1-dimensional vessel diameter.
Furthermore, velocity data can be acquired simultaneously
Figure 6 Measurements of Aortic Diameters Shown on the M-M
Measurements of aortic diameters shown on the M-mode tracing obtained at a lev
Ao  aorta; D  diastolic aortic diameter; S  systolic aortic diameter.within 1 acquisition plane in 2 aortic locations, and the pathlength (distance between the 2 aortic locations) can be
measured precisely.
To assess AD by MRI, steady-state free precession cine
imaging with electrocardiographic gating can be used to
measure the changes in cross-sectional aortic area after
aortic contouring, with a temporal resolution of 40 ms.
Alternatively, the modulus images of a similarly placed cine
gradient echo phase contrast velocity acquisition can be used
for aortic contouring and area measurements (26). The mini-
mum and maximum ascending aortic cross-sectional areas
should be measured and AD calculated as the following:
Aortic Distensibility (in cm2dyne1106)

maximum areaminimum area
minimum area	P	 1,000
where P is the pulse pressure in mm Hg (27).
Grotenhuis et al. (28) obtained AD measurements by
MRI in patients with bicuspid aortic valves and showed
significantly reduced aortic elasticity throughout the entire
thoracic aorta when compared with control subjects (Fig. 7).
Moreover, it is favorable to use central aortic pressures
instead of brachial pressures to calculate distensibility to
minimize the amplification phenomenon.
Velocity-encoded MRI with phase contrast sequences
allows accurate assessment of the blood flow velocity with a
sufficient temporal and spatial resolution to study the
propagation of the aortic systolic flow wave. Velocity-
encoded MRI, when compared directly with invasive he-
Tracing
m above the aortic cusps.ode
el 3 cmodynamic measurements, had excellent correlation and
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compared several of these noninvasive techniques used for
the assessment of the elastic properties of the aorta and
reported aortic distensibilities with MRI with central pres-
sures. Ascending aorta distensibility correlated strongly with
aortic arch MRI-derived PWV (r  0.73, p  0.0001), and
both indexes were more strongly and specifically related to
aging than applanation tonometry-derived indexes (CFPWV,
augmentation index) or carotid distensibility.
Clinical Importance and Prognostic Value of AS
Carotid-femoral PWV, a global measure of AS, has been
shown to be an independent predictor of coronary heart
disease and stroke in healthy subjects and an independent
predictor of mortality in the general population (29).
Carotid-femoral PWV is also a predictor of future changes
in systolic blood pressure (SBP) and future development of
hypertension in healthy volunteers. Thus, it might have a
role in identifying patients at risk of development of
hypertension (30). Furthermore, increased arterial stiffness
has been associated with increased morbidity and both
all-cause and cardiovascular (CV) mortality in hypertensive
patients (31,32). Cruickshank et al. (33) showed, in a
multiethnic population of patients with impaired glucose
Figure 7 Distensibility Measurement
of the Aortic Root With Cardiac MRI
(A and B) Taken in the oblique coronal plane, these images show the slice
positioning of the acquisition planes at minimal and maximal aortic flow for
distensibility measurements, respectively, thus correcting for through-plane
motion of the aortic root during contraction. Note the difference in position of
the aortic root in both images, because of cardiac motion. (C and D) Corre-
sponding area measurements in the double oblique transverse orientation.
MRI  magnetic resonance imaging. Reproduced with permission from
Grotenhuis et al. (28).tolerance and/or diabetes, that higher aortic PWV was able mto independently predict all-cause and CV mortality, more
so than SBP. Mitchell et al. (34) recently showed in a large
community-based cohort that only CFPWV predicted ma-
jor CV events. Recently, a meta-analysis including more
than 15,000 subjects confirmed that CFPWV is an inde-
pendent predictor of adverse CV events and all-cause
mortality. An increase of aortic PWV of 1 m/s raises CV
risk by more than 10% (35). The 2007 European guidelines
for the management of hypertension and guidelines for
CVD prevention in clinical practice recommend, given all
the aforementioned, aortic PWV as a test to assess target
organ damage (36,37).
AS in Other Different Disease States
Association with atherosclerosis and calcification. Arte-
riosclerosis and atherosclerosis share similar pathobiologic
processes. Because the vessel wall is progressively injured,
over a period of time, the vessel wall matrix and adjacent
cells develop reparative inflammatory processes to prevent
further damage. As a result, arterial wall calcification and
increased stiffness will occur. Coronary artery calcification is
associated with impaired aortic distensibility (38). Al-
Mallah et al. (39) recently showed that thoracic aortic
calcification is inversely correlated with thoracic AD.
Chronic kidney disease and end-stage renal disease. In-
creased global AS (measured by CFPWV) has indepen-
dently been associated with reduced creatinine clearance in
subjects with mild to severe renal insufficiency, regardless of
mean arterial pressure and other CV risk factors (40). Renal
patients have marked reduction in AD along with distur-
bances in diastolic blood flow in the aorta contributing to
reduced coronary perfusion (41).
Diabetes mellitus. Two recent small studies in type 2
diabetes mellitus patients have shown that diabetes mellitus
is independently associated with lower AD, increased
PWV, and impaired flow-mediated dilation when com-
pared with age-, sex-, and comorbidities-matched control
subjects (42,43). Results on MRI-measured distensibility of
the ascending aorta from a large multiethnic cohort of
healthy individuals confirmed that diabetic vascular altera-
tions were predominant in younger individuals (44). In
addition, increased AS has been shown to be an indepen-
dent predictor of 10-year mortality in diabetic patients (33).
ortic regurgitation. Patients with chronic aortic regurgi-
ation and preserved systolic function have increased arterial
istensibility. This could be due to greater vascular compli-
nce needed as a compensatory mechanism to lessen the
mpact of the large systolic volume ejected into conduit
rteries (45). The lack of this “compensatory distensibility”
eems to be associated with faster hemodynamic deteriora-
ion and disease progression (46).
ongenital heart disease (patients with bicuspid aortic
alve and tetralogy of Fallot). Individuals with bicuspid
ortic valve have extensive changes in the extracellular
atrix of the aortic media due to mutations in the FBN-1
h
s
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that decreased levels of FBN-1 are directly associated with
higher levels of matrix metalloproteinases and aortic aneu-
rysms, in similarity to what occurs in patients with Marfan’s
syndrome (47,48). Abnormal AS and distensibility are
present in approximately 40% of patients with bicuspid
aortic valve (49). Reduced aortic elasticity in bicuspid aortic
valve patients has been associated with worsening aortic
regurgitation and LV hypertrophy (28). These changes are
likely related to genetically abnormal elastic fibers in a
degenerated aortic medial layer. Further evidence for a
genetic component is suggested, because bicuspid aortic
valve is an autosomal dominant hereditary disease with low
penetrance (50).
In addition, children after repair of tetralogy of Fallot also
develop progressive aortic root dilation that seems to cor-
relate with increased AS measured by PWV (51).
Connective tissue disorders (Marfan syndrome and
Ehlers-Danlos syndrome). Patients with Marfan syn-
drome have genetic mutation in the FBN-1 resulting in
aortic root dilation and subsequent aortic dissection. In-
creased aortic wall stiffness seems to start early in childhood
and progresses with aging (52). Thus, tissue Doppler
imaging can be used to assess alteration of aortic mechanics
with good correlation and prediction for aortic dilation and
dissection (53). Recently, losartan has been shown in small
animal studies to blunt transforming growth factor-beta
activation, decreasing its levels and preventing aortic root
structural changes (54,55). Whether this becomes an effec-
tive treatment for Marfan syndrome patients is not clear.
Ehlers-Danlos syndrome is a group of conditions affect-
ing collagen type III metabolism, causing hyperelasticity of
joints and skin. The vascular type of Ehlers-Danlos is a rare
disease presenting as spontaneous arterial rupture usually
without dissection (56). A small study using MRI showed
that AD was reduced, whereas aortic wall thickness was
slightly increased, although only 9 of 15 subjects had
interpretable images (57).
After aortic coarctation repair. A significant percentage of
patients (20% to 40%) with successful repair of aortic
coarctation will develop persistent hypertension at rest and
during exercise. With cardiac MRI, Ou et al. (58) demon-
strated that in normotensive post-coarctation repair pa-
tients, the pre-coarctation segments continued to express
increased AS by PWV when compared with the post-
coarctation segments. Perhaps this could contribute to
aneurysmal changes seen after repair.
Hypertrophic cardiomyopathy. Patients with hypertro-
phic cardiomyopathy have significantly increased AS when
compared with normal control subjects. The presence of
macroscopic myocardial fibrosis (seen as areas of myocardial
delayed-enhancement in MRI after gadolinium injection) is
associated with further increase in AS and might adversely
affect LV performance (59). Whether AS could be another
parameter for risk stratification in these patients is
unknown. ePharmacological Interventions on AS
Several studies showed that many antihypertensive medica-
tions could improve AS, although the small sample size
limits further generalization (60).
Angiotensin-converting enzyme inhibitors. Benetos et al.
(61) demonstrated a favorable decrease in the CFPWV after
both acute (3 h after first dose) and chronic administration
(after 15 days) of ramipril. Other studies have shown similar
findings with different drugs within the same class (62,63).
The mechanism is related to the reduction of the wave
reflection and augmentation index (64) with subsequent
lowering of SBP and less adverse LV remodeling.
Angiotensin-2 receptor blockers. The role of angiotensin-2
receptor blockers on AS is not yet clear, given the small
number of studies including limited sample sizes. Two
larger studies are underway to evaluate the effects on arterial
stiffness of telmisartan alone or in combination with
ramipril (65,66).
Beta-blockers. The REASON (Regression of Arterial Stiff-
ness in a Controlled Double-Blind Study) compared perindo-
pril (2 mg/day) plus indapamide (0.625 mg/day) versus
atenolol (50 mg/day) alone for 12 months in hypertensive
subjects. At 1 year, brachial and central SBP reduction
achieved with combination therapy of angiotensin-converting
enzyme inhibitor plus diuretic was greater than that with
beta-blocker alone or even angiotensin-converting enzyme
inhibitor alone. This effect was translated into greater structural
changes of arterial stiffness more pronounced in central than in
peripheral arteries (67). Higher CFPWV was closely correlated
with higher SBP as a marker of more resistant hypertension
requiring greater antihypertensive doses. In other words, in-
creased arterial stiffening might be the reason of poor SBP
response to drug treatment (68). Nebivolol, which is a selective
beta-1 blocker with nitric oxide potentiating vasodilatory effect,
has been shown to slightly decrease the augmentation index,
when compared with atenolol (69). Whether this would result
in favorable outcomes remains to be determined.
Moreover, it is important to highlight that the heart
rate-lowering effect of beta-blockers has a major impact on
the relationship between AS and central aortic pressure. As
heart rate decreases, LV filling increases, inevitably enhanc-
ing aortic pulse augmentation (ventricular-vascular cou-
pling). Thus, in individuals with stiffened aorta (higher
aortic PWV), there is an inability of buffering the increased
stroke volume, which translates into less effective central
aortic pressure reduction seen with beta-blockers (70).
Calcium-channel blockers. The largest study to investi-
gate the effect of calcium-channel blockers on pulse pressure
is the CAFE (Conduit Artery Function Evaluation) study
(71), which examined the impact of 2 different blood
pressure-lowering regimens (atenolol  thiazide vs. amlo-
dipine perindopril) on derived central aortic pressures and
emodynamic status in 2,073 participants with hyperten-
ion and at least 3 additional risk factors. Although similar
ffects in the brachial blood pressure were seen, central
1519JACC Vol. 57, No. 14, 2011 Cavalcante et al.
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perindopril compared with atenolol  thiazide-based therapy.
As previously mentioned, this could be predominantly deter-
mined by the beta-blockers effects on heart rate and stroke
volume. No differences were seen in the small subgroup
(n  114) who had CFPWV measurements (71).
Statins. The role of statins in AS remains controversial.
Some studies have not shown important improvements in
aortic hemodynamics (72). Nevertheless, a few small ran-
domized placebo-control studies, in different populations,
have shown that statins decrease the inflammatory marker
levels in addition to having favorable effects on AD (73–75).
In addition, rosuvastatin has been shown to reduce
3-nitrotyrosine levels (a marker of peroxynitrite-mediated
oxidative stress) and to decrease aortic PWV. Interestingly,
reduction of plasma cholesterol was the only independent
predictor of reduced arterial stiffness in patients with pri-
mary hypercholesterolemia after rosuvastatin therapy (76).
Cross-link breakers. Advanced glycation end product for-
mation, which occurs with aging and diabetes, has been
implicated in increased myocardial and vascular stiffness
(Fig. 2). Advanced glycation end product cross-link break-
ers have emerged as a potential therapeutic target. Alage-
brium has been extensively studied in phase I and II studies
showing good safety and tolerability profile (77).
Kass et al. (78) demonstrated that alagebrium signifi-
cantly improved arterial compliance, CFPWV, and pulse
pressure after 8 weeks of treatment in elderly patients with
baseline vascular stiffening. These changes occurred without
disproportionate decline in mean arterial pressure, systemic
resistance, cardiac output, or heart rate. Further studies
exploring other applications such as heart failure with
preserved systolic function and arterial hypertension have
also been considered (79).
Nonpharmacological Interventions on AS
Several nonpharmacological interventions to reduce AS are
currently being investigated. The 2 most important areas
are: aerobic exercise training and continuous positive airway
pressure (CPAP).
Aerobic exercise training. Aerobic exercise training pro-
duces several beneficial changes that have been well-
reviewed elsewhere (80). Although its direct effects on AS
and diastolic function have not yet been completely under-
stood, indirect evidence seems to indicate favorable changes
in aortic hemodynamic status with both acute and chronic
exercise training (81).
Retrospective studies have shown that increased physical
activity is correlated with improved aortic PWV when
compared with age-matched sedentary control subjects
(82,83). Hundley et al. (84) have shown that older patients
with isolated diastolic heart failure have impaired AD
(beyond that which occurs with normal aging) that corre-
lates with and might contribute to severe exercise intoler-
ance. More importantly, reduced AD might also be aplausible explanation for exaggerated hypertensive response
to exercise long before hypertension is overtly manifested
(85). Another study compared the impact of different types
of aerobic exercise training on AD. Arterial stiffness was
higher in strength-trained men compared with endurance-
trained men and sedentary control men. These findings
were directly correlated to higher levels of endothelin-1.
Controversy still exists, because other studies in healthy
normotensive men have suggested that chronic resistance
training has detrimental effects on central arterial compli-
ance and LV remodeling (86). Thus, it seems that different
exercise training modalities (endurance vs. resistance train-
ing) and their duration (acute vs. chronic) have different
effects on vascular tone (87).
CPAP. Systemic arterial stiffness has been positively cor-
related with the severity of obstructive sleep apnea of worse
magnitude during the early hours of the day (88,89). How
CPAP alters systemic hemodynamic status continues to be
a subject of investigation, but recent studies have proposed
a couple of potential mechanisms. CPAP seems to improve
arterial stiffness and central blood pressure by a combination
of enhanced endothelial function and reduction in sympa-
thetic tone. CPAP treatment also increases nitric oxide
production in patients with obstructive sleep apnea (90). A
recent article by Phillips et al. (91) showed that significant
reduction in arterial stiffness and central blood pressure
occurred after initiation of CPAP. More importantly, these
findings were reversed after withdrawal from this therapy,
indicating an important link.
Future Perspectives
Aortic stiffness is now recognized as an important determi-
nant of CV morbidity and mortality. However, the plethora
of studied and reported markers of AS, the differing
modalities used to assess aortic mechanics, and the complex
interplay among measures of blood pressure and LV dy-
namics (coupling) have somewhat hampered the current
clinical impact and further development of this field. Fur-
thermore, one of the major difficulties in interpreting
changes in AS is the impact that different therapies have on
blood pressure and heart rate. Most of these studies have
been retrospective or subgroup analysis of larger clinical
trials. In addition, surrogate rather than hard CV end points
are often used; therefore, properly powered and controlled
trials are needed to better identify effective strategies asso-
ciated with improvement of aortic stiffness.
Other perspectives are also worth considering for future
research in this field:
1. Larger sample studies—the statistical power for detect-
ing significant differences in treatment groups should be
discerned more clearly.
2. Combining pharmacological and nonpharmacological
strategies might provide greater impact in reversing AS,
particularly in special populations.
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a larger normative database with threshold values. Recently,
reference and normal values for PWV from a large multi-
center European cohort (n  11,092) were published (92).
This is a major step forward and should motivate similar
efforts from other major scientific societies and expert
committees. Furthermore, establishing age- and perhaps
sex-related percentiles with cutoff points for each technique,
similar to what has been done for coronary calcification
assessment, could facilitate the future use of AS as an end
point in large clinical trials.
Conclusions
Increased arterial stiffness is an important marker of in-
creased LV load and a predictor of CV morbidity that might
precede the onset of systemic hypertension in humans.
Currently, several pharmacological therapies have been
shown to improve AS and mechanics. However, the vast
majority of trials to date were uncontrolled and/or had
limited sample sizes (i.e., 100 participants). Nonpharma-
ological approaches such as aerobic exercise training and
PAP in small studies have also shown favorable results.
uture studies testing the summation of these strategies are
eeded, because a greater magnitude of response might
ccur, altering this important CV disease phenotype.
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